Neurocrine Biosciences Announces Executive and Director Changes
Ticker: NBIX · Form: 8-K · Filed: Oct 11, 2024 · CIK: 914475
| Field | Detail |
|---|---|
| Company | Neurocrine Biosciences Inc (NBIX) |
| Form Type | 8-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $900,000, $750,000, $300,000, $450,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, executive-compensation
Related Tickers: NBIX
TL;DR
NBIX board shakeup, new execs in, some out. Watch closely.
AI Summary
Neurocrine Biosciences, Inc. announced on October 11, 2024, changes in its executive and director roles. Specifically, the company reported the departure of certain officers and directors, along with the election of new directors and adjustments to compensatory arrangements for key executives.
Why It Matters
Changes in executive and director leadership can signal shifts in company strategy, operational focus, or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- NEUROCRINE BIOSCIENCES, INC. (company) — Registrant
- October 11, 2024 (date) — Date of Report
FAQ
What specific roles have been affected by the departures and appointments?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting broad executive and director level adjustments.
Are there any details on the reasons for the departures of officers or directors?
The provided text does not specify the reasons for the departures of any officers or directors.
What is the nature of the changes in compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature or terms of these arrangements in the provided excerpt.
When did these changes become effective?
The 'Date of Report' and 'Date as of Change' are both listed as October 11, 2024, indicating the reported changes are effective as of this date.
Does this filing disclose any new board members?
Yes, the filing explicitly mentions the 'Election of Directors', indicating the addition of new members to the board.
Filing Stats: 1,302 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2024-10-11 16:02:22
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
- $900,000 — o will receive an annual base salary of $900,000 and will be eligible to receive an annu
- $750,000 — h a target grant value of approximately $750,000 that will vest in equal monthly install
- $300,000 — h a target grant value of approximately $300,000 that will vest in equal annual installm
- $450,000 — h a target grant value of approximately $450,000 that will vest in accordance with the t
Filing Documents
- nbix-20241011.htm (8-K) — 27KB
- nbix-20241011_g1.jpg (GRAPHIC) — 18KB
- 0000914475-24-000206.txt ( ) — 197KB
- nbix-20241011.xsd (EX-101.SCH) — 2KB
- nbix-20241011_lab.xml (EX-101.LAB) — 21KB
- nbix-20241011_pre.xml (EX-101.PRE) — 12KB
- nbix-20241011_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: October 11, 2024 /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer